US FDA approves denosumab for cancer therapy-induced bone loss in women with breast cancer and men with prostate cancer

Area: News
The US Food and Drug Administration (FDA) has approved denosumab (Prolia) as a treatment, for the following indications: . to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer, and . as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

Full Story →